BFLY vs GEHC: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

GEHC is the larger of the two ($36.81B market cap): the incumbent the market prices for continued execution (14.80x forward earnings, beta 0.77). BFLY is the smaller challenger ($1.47B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, BFLY fits: analysts expect its revenue to rise 20% next year, against 5% for GEHC. If you believe in profit, GEHC fits: it is expected to make money next year (14.8x forward earnings), while BFLY is still expected to post a loss.

BFLY vs GEHC: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBFLYGEHCWhat it tells you
Market cap$1.47B$36.81BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-84.6914.80Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.120.77Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range40% of range73% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book7.983.17How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BFLY and GEHC affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BFLY and GEHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BFLY and GEHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Butterfly Network (BFLY) do?

Butterfly Network designs and sells handheld ultrasound systems built on its proprietary Ultrasound-on-Chip technology, which replaces the traditional piezoelectric crystals in an ultrasound machine with a semiconductor sensor. That lets a single probe (the flagship iQ3) image the whole body and connect to a phone or tablet, and the company layers on subscription software, cloud storage, and AI tools that push clinicians toward higher-margin recurring revenue. Customers include hospitals, clinics, medical schools, and increasingly international and lower-resource settings where a $2,000-to-$5,000-range device is far cheaper than a cart-based system. A newer line, embedded revenue, comes from partners that build the chip into their own products.

Full BFLY guide

What does GE HealthCare (GEHC) do?

GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. It is one of the world's largest makers of medical imaging and diagnostic equipment. Its product portfolio spans MRI, CT, X-ray, ultrasound, and molecular imaging systems, plus contrast agents and radiopharmaceuticals used in scans, patient monitoring devices, and a growing suite of healthcare software and AI tools that help clinicians interpret images and manage care. GE HealthCare makes money by selling these large imaging systems to hospitals and clinics, and importantly through recurring revenue from service contracts, maintenance, software, and consumables like contrast media. With a large installed base of equipment worldwide, the company benefits from steady demand for diagnostics, an aging global population, and the growing role of AI in radiology. Headquartered in Chicago, it serves healthcare providers across developed and emerging markets and competes among the top global medical imaging vendors.

Full GEHC guide

BFLY vs GEHC: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BFLY drivers: Software and recurring-revenue mix shift; iQ3 probe and hardware refresh cycle.
  • GEHC drivers: Large installed base and recurring revenue; AI and software in imaging.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Butterfly remains unprofitable, with trailing net losses of roughly $54M against about $123M of revenue as of September 2026, so it depends on its roughly $122M cash balance and, potentially, future capital raises; the $150M shelf and at-the-market equity program filed in Q3 2026 could dilute shareholders if used. For GEHC, gE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases.

BFLY or GEHC: which should you pick?

If the story you believe is BFLY's (Software and recurring-revenue mix shift), BFLY is the more direct way to own it; if it is GEHC's (Large installed base and recurring revenue), GEHC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BFLY and GEHC guides.

BFLY vs GEHC: the full fundamentals

BFLY. As of November 20, 2026, Butterfly closed near $5.51 for a market cap of about $1.5B, roughly 12 times its $123M of trailing revenue, down from about 18 times in October as the shares fell. Analysts on average expect about $125M of 2026 revenue and about $150M in 2027, with fourth-quarter consensus near $33.8M of revenue and a loss of about $0.02 per share. The average analyst target in Yahoo Finance's data is about $11, from 6 analysts.

GEHC. At about $81, GE HealthCare trades near 17x trailing and 15x forward earnings and about 12.5x EV/EBITDA, a multiple that has expanded since October as the shares rallied on a Q3 beat and raised guidance. Investors weigh steady diagnostics demand, recurring service revenue and AI-driven upgrades against hospital capital-spending cycles and spinoff debt. The 20-analyst mean target is about $88, and Q4 consensus is near $1.56 of EPS.

Headline figures (approximate, November 2026): BFLY shows revenue (ttm) ~$123M, q3 2026 revenue growth ~52% YoY (~$32.6M), gross margin (ttm / q3 2026) ~70% / ~73%, net loss (ttm) ~$54M; GEHC shows revenue (ttm) ~$21.6 billion, revenue growth (q3 2026, yoy) ~7%, operating margin ~14%, net income (ttm) ~$2.15 billion.

The bottom line: BFLY vs GEHC

BFLY and GEHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BFLY and GEHC exposure against your real portfolio. It is not an investment adviser.

Wondering how BFLY or GEHC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Butterfly Network

Ask Walnut's AI anything about BFLY and see how it fits what you own.

FAQ

What is the difference between BFLY and GEHC?

+

Butterfly Network designs and sells handheld ultrasound systems built on its proprietary Ultrasound-on-Chip technology, which replaces the traditional piezoelectric crystals in an ultrasound machine with a semiconductor sensor. GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BFLY or GEHC the better stock?

+

Neither is universally better. GEHC is the larger incumbent; BFLY is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BFLY or GEHC?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BFLY and GEHC?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BFLY vs GEHC?

+

BFLY: Butterfly remains unprofitable, with trailing net losses of roughly $54M against about $123M of revenue as of September 2026, so it depends on its roughly $122M cash balance and, potentially, future capital raises; the $150M shelf and at-the-market equity program filed in Q3 2026 could dilute shareholders if used. The point-of-care ultrasound market is competitive, with GE HealthCare, Philips, Clarius, Exo, and others fielding rival handheld devices, which can pressure pricing and adoption. Revenue is lumpy because it leans on hardware launch cycles, large institutional orders and a small number of embedded partners; fourth-quarter guidance implies a possible sequential decline. The stock trades near 12 times trailing sales and 8 times book value and has fallen about 39% in three months, showing how sharp drawdowns can be. Insiders sold shares in November 2026. Newer projects such as the brain-computer interface work are early and unproven, and regulatory, reimbursement, and clinical-adoption dynamics add further uncertainty to the timeline for profitability. GEHC: GE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases. It faces intense competition from Siemens Healthineers, Philips, and others, and pricing pressure in mature imaging categories. Supply chain disruptions and component shortages can affect deliveries. As a recently independent company, it carries debt from the spinoff (Yahoo shows about $10.4 billion of debt against $2.8 billion of cash) and must execute on its own strategy. Regulatory approval, reimbursement changes, and product recalls are risks in medical devices, and pipeline agents such as mangaciclanol can still fail in late-stage trials. Currency swings affect its global revenue. Margins in hardware can be modest, and growth depends on successfully expanding higher-margin software, services, and contrast media against capable, well-resourced competitors. Quarterly results were uneven early in 2026, and after a 14% one-month rally the stock now prices in more of the recovery, which leaves less cushion if a quarter disappoints.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BFLY or GEHC; figures are approximate and dated (as of November 2026). Verify current data before investing.